Evidence map›Paper›PMID 26921415›Full record

ArticleAntimicrobial agents and chemotherapy2016

Erratum for Kamal et al., A Drug-Disease Model Describing the Effect of Oseltamivir Neuraminidase Inhibition on Influenza Virus Progression.

Mohamed A Kamal, Ronald Gieschke, Annabelle Lemenuel-Diot, Catherine A A Beauchemin, Patrick F Smith, Craig R Rayner

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Mohamed A KamalDepartment of Clinical Pharmacology, Roche Pharmaceutical Research and Early Development, New York City, New York, USA.
Ronald GieschkeDepartment of Clinical Pharmacology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Annabelle Lemenuel-DiotDepartment of Clinical Pharmacology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Catherine A A BeaucheminDepartment of Physics, Ryerson University, Toronto, Ontario, Canada.
Patrick F SmithMonash Institute of Pharmaceutical Sciences, Melbourne, Australia d3 Medicine LLC, Parsippany, New Jersey, USA.
Craig R RaynerMonash Institute of Pharmaceutical Sciences, Melbourne, Australia University at Buffalo, School of Pharmacy and Pharmaceutical Sciences, Buffalo, New York, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID26921415
PMCPMC4775932

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.